Pfizer SARS-COV-2 - Clinical Trial

What is the Purpose of this Study?

We are doing this study to test the effectiveness and safety of this vaccine.

What is the Condition Being Studied?

New trial vaccine for COVID-19

Who Can Participate in the Study?

-Healthy Adults
-18-85 year old

For more information about who can be in this study, please contact the study team.

Age Group

What is Involved?

If you choose to join the study, you will:
-Be randomly assigned to either Group 1 or Group 2:
--Group 1 will get two shots of the COVID-19 study vaccine
--Group 2 will get two placebo injections (Harmless shot that does not have any vaccine in it)
- Both groups will be given their shots either 3 weeks or 2 months apart
- Complete follow up visits after each vaccination
- Have several blood draws
- Keep an Electronic Diary (eDiary) to track your temperature and symptoms

Study Details

Full Title
A PHASE 1/2, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND, DOSE-FINDING STUDY TO DESCRIBE THE SAFETY, TOLERABILITY, IMMUNOGENICITY, AND POTENTIAL EFFICACY OF SARS-COV-2 RNA VACCINE CANDIDATES AGAINST COVID-19 IN HEALTHY ADULTS
Principal Investigator
Pediatric Infectious Diseases Specialist
Protocol Number
IRB: PRO00105644
NCT: NCT04368728
Phase
Phase I/II
ClinicalTrials.gov
Contact the Duke Recruitment Innovation Center
MyResearchPartners@duke.edu
or
919-681-5698